# US 2025/0082630 A1 · Methods of treating brain tumours and neuroblastomas

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082630 A1
- Document ID: US20250082630A1
- Status: Published application
- Kind: A1
- Application number: 18/721,997
- Filed: 2022-12-20
- Published: 2025-03-13
- Earliest claimed: 2021-12-21
- Assignees: AstraZeneca AB
- Applicants: AstraZeneca AB
- Inventors: Petra HAMERLIK
- Web page: https://patentgrep.com/patent/US20250082630A1

## CPC

- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/00: Radiation therapy (ultrasound therapy A61N7/00; devices or apparatus applicable to both therapy and diagnosis A61B6/00)
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a substituted azaquinolone compounds having activity as a poly(ADP-ribose) polymerase (PARP) inhibitor.

## Claims

### Claim 1

1) A method of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a poly(ADP-ribose) polymerase (PARP) inhibitor,
wherein the brain tumour or neuroblastoma comprises an alpha thalassemia/mental retardation syndrome X-linked (ATRX) deficient phenotype,
wherein the PARP inhibitor is a compound of Formula I
wherein:
R1 is independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C1-4 fluoroalkyl, and C1-4 alkyloxy;
R2 is independently selected from H, halo, C1-4 alkyl, and C1-4 fluoroalkyl; and
R3 is H or C1-4 alkyl;
R4 is halo or C1-4 alkyl,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

2) The method of claim 1, wherein the brain tumour or neuroblastoma further comprises an isocitrate dehydrogenase 1 and/or 2 (IDH1 and/or IDH2) deficient phenotype.

### Claim 3 (depends on 1)

3) The method of claim 1, wherein the brain tumour or neuroblastoma does not comprise an IDH1 deficient phenotype.

### Claim 4 (depends on 1, 2, 3)

4) The method of any one of claims 1 to 3, wherein the brain tumour or neuroblastoma comprises O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation.

### Claim 5

5) The method of any one of the preceding claims, further comprising a step of diagnosing the patient as having the brain tumour or neuroblastoma comprising the ATRX deficient phenotype prior to administering the PARP inhibitor.

### Claim 6 (depends on 5)

6) The method of claim 5, wherein the step of diagnosing the patient further comprises determining whether the brain tumour or neuroblastoma further comprises the IDH1 or IDH2 deficient phenotype and/or MGMT promoter methylation.

### Claim 7 (depends on 5, 6)

7) The method of claim 5 or claim 6, wherein diagnosing the patient comprises assaying cells obtained from the brain tumour or neuroblastoma from the patient.

### Claim 8

8) The method of any one of the preceding claims, wherein the PARP inhibitor is administered to the patient in combination with
i) an alkylating chemotherapeutic agent; and/or
ii) ionizing radiation.

### Claim 9

9) A method of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a poly(ADP-ribose) polymerase (PARP) inhibitor, and
i) an alkylating chemotherapeutic agent; and/or
ii) ionizing radiation administered at a dose of 10 Gy or above,
wherein the PARP inhibitor is a compound of Formula I
wherein:
R1 is independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C1-4 fluoroalkyl, and C1-4 alkyloxy;
R2 is independently selected from H, halo, C1-4 alkyl, and C1-4 fluoroalkyl; and
R3 is H or C1-4 alkyl;
R4 is halo or C1-4 alkyl,
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

10) The method of claim 9, wherein the brain tumour or neuroblastoma comprises:
(i) an alpha thalassemia/mental retardation syndrome X-linked (ATRX) deficient phenotype;
(ii) an isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) deficient phenotype; and/or
(iii) O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation.

### Claim 11 (depends on 8, 9, 10)

11) The method of any one of claims 8 to 10, wherein the alkylating chemotherapeutic agent is temozolomide (TMZ) or dianhydrogalactitol (VAL-083).

### Claim 12 (depends on 11)

12) The method of claim 11, wherein TMZ is administered at:
(i) a dose of less than about 200 mg/m2, a dose of less than about 150 mg/m2, a dose of less than about 125 mg/m2, or less than about 100 mg/m2;
(ii) a dose of between about 50 and 150 mg/m2, a dose of between about 75 and 150 mg/m2, or a dose of between about 50 mg/m2 and 125 mg/m2.

### Claim 13 (depends on 11)

13) The method of claim 11, wherein VAL-083 is administered at:
(i) a dose of less than about 50 mg/m2, a dose of less than about 40 mg/m2, a dose of less than about 30 mg/m2, or less than about 20 mg/m2;
(ii) a dose of between about 10 and 50 mg/m2, a dose of between about 10 and 40 mg/m2, or a dose of between about 10 mg/m2 and 30 mg/m2.

### Claim 14 (depends on 8, 9, 10, 11, 12, 13)

14) The method of any one of claims 8 to 13, wherein the ionizing radiation is administered at:
(i) a dose of less than about 60 Gy, less than about 55 Gy, less than about 50 Gy, less than about 45 Gy, or less than about 40 Gy; or
(ii) a dose of between about 20 Gy and about 60 Gy, between about 20 Gy and about 55 Gy, between about 20 Gy and about 50 Gy, between about 20 and about 45 Gy, or between about 20 and about 40 Gy, between about 30 Gy and about 60 Gy, between about 30 Gy and about 55 Gy, between about 30 Gy and about 50 Gy, between about 30 Gy and about 45 Gy, between about 30 Gy and about 40 Gy optionally wherein the dose of ionizing radiation is administered as fractionated radiotherapy.

### Claim 15 (depends on 8, 9, 10, 11, 12, 13, 14)

15) The method of any one of claims 8 to 14, wherein the PARP inhibitor synergistically potentiates the activity of the alkylating chemotherapeutic agent and/or radiotherapeutic agent.

### Claim 16 (depends on 8, 9, 10, 11, 12, 13, 14, 15)

16) The method of any one of the claims 8 to 15, wherein the PARP inhibitor treats the brain tumour or neuroblastoma independent of any effect on the glioma induced by administration of the chemotherapeutic or radiotherapeutic agents.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

17) The method according to any one of claims 1 to 16 wherein R1 is selected from any one of methyl, ethyl, isopropyl, cyclopropyl, 1,1-difluoroethyl, 1-fluoroethyl, trifluoromethyl, difluoromethyl, and methoxy.

### Claim 18 (depends on 17)

18) The method according to claim 17 wherein R1 is methyl or ethyl.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

19) The method according to any one of claims 1 to 18 wherein R2 is selected from any one of H, chloro, fluoro, methyl, and difluoromethyl.

### Claim 20 (depends on 19)

20) The method according to claim 19 wherein R2 is fluoro or methyl.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

21) A compound The method according to any one of claims 1 to 20 wherein R3 is methyl or ethyl.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

22) The method according to any one of claims 1 to 21 wherein R4 is selected from any one of chloro, fluoro and methyl.

### Claim 23 (depends on 22)

23) The method according to claim 22 wherein R4 is fluoro.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

24) The method according to any one of claims 1 to 16 wherein R1 is C1-4 alkyl, R2 is halo, R3 is C1-4 alkyl, R4 is halo or C1-4 alkyl, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

25) The method according any one of claims 1 to 16 wherein the PARP inhibitor is selected from selected from:
5-[4-[(2,5-dimethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-fluoro-N-methyl-pyridine-2-carboxamide,
5-[4-[(2,5-dimethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
6-chloro-5-[4-[(2,5-dimethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(2,5-dimethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
5-[4-[(2,5-dimethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-fluoro-pyridine-2-carboxamide,
5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-methyl-pyridine-2-carboxamide,
5-[4-[(2,5-dimethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-methyl-pyridine-2-carboxamide,
6-chloro-5-[4-[(5-chloro-2-ethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(5-chloro-2-ethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-fluoro-N-methyl-pyridine-2-carboxamide,
5-[4-[(5-chloro-2-ethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(5-chloro-2-ethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
6-fluoro-5-[4-[[5-fluoro-2-[(1S and 1R)-1-fluoroethyl]-3-oxo-4H-quinoxalin-6-yl]methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[[5-fluoro-2-[(1S and 1R)-1-fluoroethyl]-3-oxo-4H-quinoxalin-6-yl]methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
5-[4-[(5-chloro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(5-chloro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-fluoro-N-methyl-pyridine-2-carboxamide,
5-[4-[(5-chloro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
5-[4-[[2-(1,1-difluoroethyl)-5-fluoro-3-oxo-4H-quinoxalin-6-yl]methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
6-(difluoromethyl)-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]pyridine-2-carboxamide,
5-[4-[(2-ethyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
6-(difluoromethyl)-5-[4-[(2-ethyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(2-ethyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]pyridine-2-carboxamide,
5-[4-[(2-ethyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-methyl-pyridine-2-carboxamide,
5-[4-[(2-ethyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-fluoro-N-methyl-pyridine-2-carboxamide,
6-chloro-5-[4-[(2-ethyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(2-ethyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
6-chloro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
6-chloro-5-[4-[(5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
6-fluoro-5-[4-[(5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[[2-(difluoromethyl)-5-fluoro-3-oxo-4H-quinoxalin-6-yl]methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
5-[4-[(5-fluoro-2-methoxy-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
6-fluoro-5-[4-[(5-fluoro-2-methoxy-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(5-fluoro-2-methoxy-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
6-chloro-5-[4-[(5-fluoro-2-methoxy-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(2-ethyl-5-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
5-[4-[(2-ethyl-5-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-fluoro-N-methyl-pyridine-2-carboxamide,
5-[4-[(2-ethyl-5-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
N-ethyl-6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]pyridine-2-carboxamide,
N-ethyl-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-methyl-pyridine-2-carboxamide,
5-[4-[[5-fluoro-3-oxo-2-(trifluoromethyl)-4H-quinoxalin-6-yl]methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
6-fluoro-5-[4-[[5-fluoro-3-oxo-2-(trifluoromethyl)-4H-quinoxalin-6-yl]methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
6-chloro-5-[4-[[5-fluoro-3-oxo-2-(trifluoromethyl)-4H-quinoxalin-6-yl]methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[[5-fluoro-3-oxo-2-(trifluoromethyl)-4H-quinoxalin-6-yl]methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
6-fluoro-5-[4-[(5-fluoro-2-isopropyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(5-fluoro-2-isopropyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
5-[4-[(5-fluoro-2-isopropyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(2-cyclopropyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-6-fluoro-N-methyl-pyridine-2-carboxamide,
5-[4-[(2-cyclopropyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
5-[4-[(2-cyclopropyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
5-[4-[(2-methoxy-5-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethyl-pyridine-2-carboxamide,
6-fluoro-5-[4-[(2-methoxy-5-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
6-(difluoromethyl)-5-[4-[(2-methoxy-5-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide, and
6-(difluoromethyl)-5-[4-[(2,5-dimethyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide,
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

26) The method according to any one of claims 1 to 16 wherein the PARP inhibitor is:
6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

27) The method according to any one of claims 1 to 16 wherein the PARP inhibitor is:
6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

28) The method according to any one of the claims 1 to 27, wherein the brain tumour is a glioma or an ependymoma.

### Claim 29 (depends on 28)

29) The method according to claim 28, wherein the brain tumour is a glioma.

### Claim 30 (depends on 29)

30) The method according to claim 29, wherein the glioma is a paediatric glioma.

### Claim 31 (depends on 29, 30)

31) The method according to claim 29 or claim 30, wherein the glioma is a high grade glioma, optionally selected from the list consisting of: an oligodendroglioma, an anaplastic astrocytoma, a glioblastoma, and a diffuse midline glioma.

### Claim 32 (depends on 29, 30, 31)

32) The method according to any one of claims 29 to 31, wherein the glioma is a H3K27M mutant glioma.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

33) The method according to any one of the claims 1 to 27, wherein the brain tumour or neuroblastoma is characterised as having a high level of genomic instability.
